An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer. World J Gastrointest Oncol 2024; 16(6): 2449-2462 [PMID: 38994132 DOI: 10.4251/wjgo.v16.i6.2449]
Corresponding Author of This Article
Rui-Hua Zhao, PhD, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Road, Zhengzhou 450000, Henan Province, China. zrh_ly@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2449-2462 Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2449
Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer
Tian-Qi An, Hui Qiu, Quan-Bo Zhou, Hong Zong, Shuang Hu, Yu-Gui Lian, Rui-Hua Zhao
Tian-Qi An, Hong Zong, Shuang Hu, Rui-Hua Zhao, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Hui Qiu, Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing 100000, China
Quan-Bo Zhou, Yu-Gui Lian, Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Co-first authors: Tian-Qi An and Hui Qiu.
Co-corresponding authors: Yu-Gui Lian and Rui-Hua Zhao.
Author contributions: Zhao RH, Lian YG and Zong H conceptualized and designed the research; An TQ, Qiu H, Zhou QB and Hu S screened patients and acquired clinical data; Zhao RH, An TQ and Qiu H performed Data analysis; An TQ, Qiu H, Zhao RH, and Lian YG wrote the paper; All the authors have read and approved the final manuscript. An TQ and Qiu H were responsible for patient screening, enrollment, and collection of clinical data. Both authors have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the paper. Both Zhao RH and Lian YG have played important and indispensable roles in the study design, data interpretation and manuscript preparation as the co-corresponding authors. Zhou QB searched the literature, revised and submitted the early version of the manuscript. Hu S and Zong H were instrumental and responsible for data re-analysis and re-interpretation, figure plotting, comprehensive literature search, preparation and submission of the current version of the manuscript. This collaboration between Hu S and Zong H is crucial for the publication of this manuscript and other manuscripts still in preparation.
Institutional review board statement: The study was approved by the Clinical Research Ethics Committee of the First Hospital of Zhengzhou University (No. 2022-KY-0910-001).
Informed consent statement: Patient informed consent was not needed as our study was retrospective.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data are publicly available for sharing use.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui-Hua Zhao, PhD, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Road, Zhengzhou 450000, Henan Province, China. zrh_ly@163.com
Received: December 20, 2023 Revised: February 20, 2024 Accepted: April 7, 2024 Published online: June 15, 2024 Processing time: 178 Days and 0.5 Hours
Core Tip
Core Tip: Fruquintinib (F) and regorafenib (R) monotherapy or in combination with programmed death-1 (PD-1) inhibitors, are commonly used treatment options for microsatellite stable or proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC). Nowadays, there is limited research data comparing the efficacy of F plus PD-1 inhibitors (FP) and R plus PD-1 inhibitors (RP) to F and R monotherapy. And there is also no consensus on whether combination therapy is more effective than monotherapy. We included a total of 313 patients with MSS/pMMR metastatic CRC (mCRC) who received at least third-line treatment with F, R, FP, or RP at our hospital, and then conducted statistical analysis on their clinical data and prognosis. And then found that the FP regimen has the potential to yield favorable survival benefits for MSS/pMMR mCRC, making it worthy of further research and investigation.
